electroCore Expands Intellectual Property Portfolio

ROCKAWAY, N.J., March 30, 2026 — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the issuance of two new U.S. patents that further bolster the Company’s already extensive intellectual property portfolio. These additions underscore electroCore’s position as a leader in non-invasive vagus nerve stimulation (nVNS) technology and demonstrate how a nimble small-cap innovator can build one of the most robust patent portfolios in the field. The newly issued patents are:

• U.S. Patent No. 12,208,263, entitled “Devices and Methods for Vagal Nerve Stimulation” was issued on January 28, 2026 and covers innovative methods for modulating the vagus nerve, including positioning an electrode in contact with an electrically conductive gel on the neck of the user, delivering an electrical impulse to the vagus nerve, and dynamically adjusting the electrode position based on the pressure sensation felt by the user.

• U.S. Patent No. 12,213,795, entitled “Devices and Methods for Remote Therapy and Patient Monitoring” was issued on February 4, 2026 and covers systems and methods for modulating a nerve that include storing data related to parameters of the electrical impulse applied to the nerve, collecting user status data from the patient, and comparing that data with the impulse parameters to optimize therapy and enable remote monitoring.

“These two new patents are a powerful demonstration of electroCore’s commitment to innovation and IP protection,” said Joshua Lev, Interim President & CFO of electroCore. “We have built a truly extensive patent portfolio that now includes a multitude of issued patents covering our core gammaCore™ and gammaCore Sapphire™ nVNS platforms, as well as related wellness products such as TAC-STIM™ and Truvaga 350™. These new patents are a part of electroCore’s expanding portfolio which, together with pending applications, potentially extend some of its patent terms until at least 2039, safeguarding our market position in next-generation therapies for migraine, cluster headache, and a growing range of wellness and medical indications.”

With these additions, electroCore’s patent estate encompasses more than 160 issued U.S. patents together with numerous pending applications in the U.S. and internationally, specifically protecting its pioneering nVNS technology. This breadth of protection—spanning device design, stimulation waveforms, treatment methods, patient interfaces, and remote-monitoring capabilities—provides a formidable barrier to competition and creates multiple layers of exclusivity well into the 2040s.

About electroCore, Inc.

electroCore, Inc. and its subsidiaries (“electroCore” or the “Company”) is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products are gammaCore non-invasive vagus nerve stimulation, or nVNS, for the management and treatment of certain primary headache conditions, and Quell Fibromyalgia for the reduction of fibromyalgia symptoms. Additionally, the Company commercializes its handheld and personal use Truvaga and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance. For more information, visit www.electrocore.com.

Contact

ECOR Investor Relations (973) 302-9253 [email protected]